Targeted Therapies in Early Stage NSCLC: Hype or Hope?

MYC, MYCL, and MYCN as therapeutic targets in lung cancer

(2020) Daniel Massó-Vallés et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

(2020) David S Hong et al.   LANCET ONCOLOGY

KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures

(2020) Alex Friedlaender et al.   CANCER TREATMENT REVIEWS

Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non–small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.

(2020) Harry J.M. Groen et al.   JOURNAL OF CLINICAL ONCOLOGY

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial.

(2020) Yi-Long Wu et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.

(2020) Egbert F. Smit et al.   JOURNAL OF CLINICAL ONCOLOGY

Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.

(2020) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

(2020) Paul K. Paik et al.   NEW ENGLAND JOURNAL OF MEDICINE

A BRAF new world

(2020) Daniele Frisone et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

The METeoric rise of MET in lung cancer

(2020) Alex Friedlaender et al.   CANCER

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

(2020) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting Cancer Cell Dormancy

(2019) Ariadna Recasens et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC

(2019) Alex Friedlaender et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

363OTreatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC)

(2019) D H Lee et al.   ANNALS OF ONCOLOGY

LBA5_PROsimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis

(2019) S S Ramalingam et al.   ANNALS OF ONCOLOGY

Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients

(2019) Liwen Xiong et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial

(2019) Alice T Shaw et al.   LANCET ONCOLOGY

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

(2019) Robert C Doebele et al.   LANCET ONCOLOGY

Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario

(2018) Alfredo Addeo et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2)EGFRMutation‐Positive Non‐Small Cell Lung Cancer: A Prospective, Single‐Arm, Phase II Study

(2018) Liwen Xiong et al.   ONCOLOGIST

Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial

(2018) Dongsheng Yue et al.   Lancet Respiratory Medicine

Dormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer

(2018) François M. Vallette et al.   BIOCHEMICAL PHARMACOLOGY

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer

(2018) Nathan A. Pennell et al.   JOURNAL OF CLINICAL ONCOLOGY

Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling

(2017) Aadel A. Chaudhuri et al.   Cancer Discovery

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

(2016) Jacob J. Chabon et al.   Nature Communications

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

(2015) Karen Kelly et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status

(2015) Wenzhao Zhong et al.   Journal of Hematology & Oncology

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data

(2014)   LANCET

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

(2014) Yi-Long Wu et al.   LANCET ONCOLOGY

Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study

(2013) Glenwood D. Goss et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

(2012) Julian R. Molina et al.   MAYO CLINIC PROCEEDINGS

Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design

(2011) J. E. Chaft et al.   CLINICAL CANCER RESEARCH

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

(2011) Masahiro Fukuoka et al.   JOURNAL OF CLINICAL ONCOLOGY

Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer

(2011) Humberto Lara-Guerra et al.   LUNG CANCER

Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data

(2010)   LANCET

Phase II Study of Preoperative Gefitinib in Clinical Stage I Non–Small-Cell Lung Cancer

(2009) Humberto Lara-Guerra et al.   JOURNAL OF CLINICAL ONCOLOGY

Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

(2008) Jean-Pierre Pignon et al.   JOURNAL OF CLINICAL ONCOLOGY